Clinical Trial Update: Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype [Phase 2]

View source ↗

Summary

A Phase 2 trial of nivolumab in IDH-mutant gliomas, with and without hypermutator phenotype, has results posted on ClinicalTrials.gov.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma
• High-grade Glioma
• Low-grade Glioma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Glioma, Glioblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-24